Vinge advises Vimian Group AB (publ) (“Vimian”) in connection with a new EUR 330 million multicurrency revolving facility agreement and its issuance of senior unsecured bonds in an amount of EUR 150 million (within a framework of EUR 250 million)
The revolving credit facility and the proceeds from the bonds will be used, inter alia, to refinance Vimian’s existing multicurrency term and revolving facilities agreement and to finance general corporate purposes.
The credit facility, arranged by Nordea Bank Abp, filial i Sverige, DNB Bank ASA, Sweden Branch and Skandinaviska Enskilda Banken AB (publ), consists of a multicurrency revolving credit facility of EUR 330,000,000 (with an up to EUR 100,000,000 uncommitted incremental facility). The agreement has a three-year term, with the possibility of an extension.
The bonds have a tenor of three years and were issued with a coupon of EURIBOR 3m plus 200 basis points. The bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm. DNB Carnegie Investment Bank AB (publ), Nordea Bank Abp, and Skandinaviska Enskilda Banken AB (publ) acted as joint bookrunners in connection with the bond issuance.
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. Vimian’s shares are listed on Nasdaq Stockholm.
Vinge’s team consisted of Albert Wållgren, Linn Adelwald, Lionardo Ojeda and William Carlberg Johansson.
